• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention reacts a compound of formula II with a compound of formula III in the presence of zinc, iodine and / or Lewis acid and an aprotic organic solvent Converting to an additional salt or base salt), or a method for preparing a compound of formula (I) or an acid addition salt or base salt thereof: Formula I Formula II Formula III Where R is phenyl optionally substituted with 1 to 3 substituents each independently selected from halo and trifluoromethyl; R 1 is C 1 -C 6 alkyl; "Het" is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, oxo, benzyl and benzyloxy; X is chloro, bromo or iodo.
    公开号:KR19990036174A
    申请号:KR1019980700842
    申请日:1996-07-26
    公开日:1999-05-25
    发明作者:마이클 부터스；줄리 앤 해리슨；알란 존 페트만
    申请人:디. 제이. 우드, 무어 제임스 더블유；화이자 리써치 앤드 디벨로프먼트 캄파니 엔.브이. 에스.에이；
    IPC主号:
    专利说明:

    Process for preparing triazole by adding organometallic to ketone and intermediates therefor
    It is well known in the field of organic chemistry to react aldehydes and ketones with organometallic compounds derived from alkyl halides to form secondary and tertiary alcohols, respectively. Many different metals and metal derivatives such as lithium, magnesium, aluminum, tin, zinc and their salts have been reported to be useful in this type of reaction. A. R. Gangloff et al. J. Org. Chem., 57 4797-4799 (1992) discloses an organic zinc derivative in which 2- (bromomethyl) -4-carbetoxy-1,3-oxazole is reacted with zinc powder to nucleophilic addition reaction with aldehydes and ketones. It is disclosed to form a. In addition, Collet et al., Synth. Comm., 19 (11 and 12) 2167-2173 (1989), report the reaction of aldehydes and organic zinc derivatives of ketones and bromoesters.
    Certain compounds prepared in accordance with the process of the invention are disclosed in EP 0357241 and EP 0440372.
    Surprisingly, certain 1-phenyl-2- (1H-1,2,4-triazol-1-yl) ethanone derivatives are derived from certain alpha-haloalkylpyridine derivatives, using reaction conditions particularly suitable for bulk synthesis of the product. It has been found that the reaction with the derived organometallic compounds may form tertiary alcohols of high stereoselectivity in good to good yields.
    This finding is attributed to (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1, which is a compound with antifungal activity. (2R, 3S / 2S, 3R) -3- (4-chloro-5-fluoropyrimidin-6-yl), an important intermediate in the preparation of 2,4-triazol-1-yl) butan-2-ol It has been shown to be particularly useful for the synthesis of -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol. The synthesis of these two compounds is disclosed in European Patent Application Publication No. 0440372. In this patent application, organolithium derivatives of 4-chloro-6-ethyl-5-fluoropyridinine at -70 to -50 ° C are treated with 1- (2,4-difluorophenyl) -2- (1H-1 Two pairs of enantiomers obtained by addition to, 2,4-triazol-1-yl) ethanone were chromatographed to give (2R, 3S / 2S, 3R) -3- (4-chloro-5-fluoro Pyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol is prepared. The best stereoselectivity obtained with this addition has an enantiomeric pair of 2R, 3S / 2S, 3R predominantly at a molar ratio of 1.1: 1 and the total isolation yield of all four stereoisomers is only about 50%, which is low The yield is thought to be because this reaction occurs competitively with the enolation reaction. These factors, namely the necessity of carrying out the addition reaction under very dilute conditions at very low temperatures and the 2R, 3R / 2S, 3S enantiomer pair, are not intended, but the two pairs of enantiomers at the end of the reaction (2R, 3S / 2S) Coupled with the difficulty of separating, 3R- and 2R, 3R / 2S, 3S-) in approximately equal amounts, this method is an economical way to make large quantities of 2R, 3S / 2S, 3R intermediates that require this method. It means not appropriate.
    In contrast, 3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl, for example, under the reaction conditions of the present invention which are well suited for synthesizing products in large quantities. 9-1 is a 2R, 3S / 2S, 3R enantiomer pair and a 2R, 3R / 2S, 3S enantiomer pair of 9: (1H-1,2,4-triazol-1-yl) butan-2-ol Obtained in a molar ratio of, it was found that all enantiomers (as hydrochloride) can be obtained with a total isolation yield of 65%.
    However, higher isolation yields were obtained by varying the reaction conditions in accordance with the present invention, and higher molar ratios (in the same reaction system and for the isolated product) were measured.
    Similar results were obtained with various alpha-haloalkylpyrimidine substrates.
    The yield and stereoselectivity obtained bring significant economic advantages.
    The present invention relates to a process for the preparation of alcohols by the addition of organometallic reagents to ketones. More specifically, the present invention provides a tertiary reaction by reacting an organometallic compound derived from alpha-haloalkylpyrimidine with 1-phenyl-2- (1H-1,2,4-triazol-1-yl) ethanone derivative. It relates to a method of preparing alcohol.
    The present invention reacts a compound of formula II with a compound of formula III in the presence of zinc, iodine and / or Lewis acid and an aprotic organic solvent, and then optionally forms an acid addition salt or base salt of the product A process for the preparation of a compound of formula (I) or an acid addition salt or base salt thereof:
    Where
    R is phenyl optionally substituted with 1 to 3 substituents each independently selected from halo and trifluoromethyl;
    R 1 is C 1 -C 6 alkyl;
    “Het” is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, oxo, benzyl and benzyloxy.
    Where
    R is as defined above for the compound of formula (I).
    Where
    R 1 and “Het” are as defined above for the compound of Formula I,
    X is chloro, bromo or iodo.
    Optionally, lead may also be present in the reactants as the metal itself or in the form of a suitable salt (eg, second lead halide). Lead may be added individually or may be present essentially in the zinc used.
    In the above definition, alkyl and alkoxy groups having 3 or more carbon atoms may be straight or branched, and "halo" means fluoro, chloro, bromo or iodo.
    Preferably, R is phenyl optionally substituted with one to three halo substituents. More preferably R is phenyl substituted with one or two substituents each independently selected from fluoro and chloro. Even more preferably R is phenyl substituted with one or two fluoro substituents. Most preferably R is 2,4-difluorophenyl.
    Preferably, R 1 is C 1 -C 4 alkyl. More preferably R 1 is methyl or ethyl. Most preferably, R 1 is methyl.
    Preferably, "Het" is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from halo, oxo and benzyl. More preferably, "Het" is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from fluoro, chloro, oxo and benzyl. Even more preferably, "Het" is pyrimidinyl substituted with 1 to 3 substituents each independently selected from fluoro and chloro.
    Preferred examples of "Het" are pyrimidin-4-yl, 4-chloro-5-fluoropyrimidin-6-yl, 5-fluoropyrimidin-4-yl, 2-chloro-5-fluoropyrimidine -6-yl, 2,4-dichloro-5-fluoropyrimidin-6-yl, 4-chloropyrimidin-6-yl and 1-benzyl-5-fluoropyrimidin-6-one-4-yl to be. Most preferably "Het" is 4-chloro-5-fluoropyrimidin-6-yl.
    Preferably, X is bromo or iodo. Most preferably, X is bromo.
    The compound of formula (II) may be an enolable ketone. Most preferably, the compound of formula II is 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone.
    Preferably, the compound of formula III is 6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine, 6- (1-bromoethyl) -4-chloro-5-fluoropyri Midine, 6- (1-bromoethyl) -2-chloro-5-fluoropyrimidine, 4- (1-bromoethyl) pyrimidine, 4- (1-bromoethyl) -6-chloropyrimidine , 4- (1-bromoethyl) -5-fluoropyrimidine and 1-benzyl-4- (1-bromoethyl) -5-fluoropyridin-6-one.
    Most preferably, the compound of formula III is 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine.
    The reaction is carried out in the presence of a suitable aprotic organic solvent such as tetrahydrofuran, toluene, 1,2-dimethoxyethane or methylene chloride or a mixture of two or more thereof. It is highly desirable that the solvent be dried prior to use to substantially remove all traces of water. Drying agents such as magnesium sulfate, sodium sulfate or molecular sieves may be used, or may be dried by distillation from metals such as lithium, sodium or potassium, or by azeotropic distillation.
    Preferred solvent for this reaction is tetrahydrofuran.
    It is also preferable to carry out the reaction under anhydrous inert atmosphere such as using anhydrous nitrogen or argon gas.
    The zinc used in the reaction may be zinc powder derived from commercially available raw materials or may be newly produced in situ by reducing zinc halides (eg zinc chloride) with lithium, sodium or potassium (RD). Rieke, Acc. Chem. Res., 10, 301 (1977). The zinc powder may be activated by stirring the powder slurry in a suitable solvent (eg tetrahydrofuran) for several hours before use.
    Optionally, the present invention is practiced in the presence of additional lead.
    Commercially available zinc powders contain small amounts of lead as impurities and the content of lead may vary up to about 2000 parts per million (0.20 wt.%), Depending on the source. However, it is generally desirable to increase the content of lead by adding lead to the reaction mixture in the form of lead powder. Lead powder is commercially available.
    Preferably, when lead is used, the content of lead in the reactants is at least 2000 ppm (0.2% by weight) relative to the amount of zinc present. More preferably, the amount of lead present is 2000 to 100,000 ppm (0.2 to 10% by weight). Most preferably, the amount of lead present is about 50,000 ppm (5% by weight).
    Iodine is generally used commercially available crystalline form. The role of iodine during the reaction is to generate zinc iodide in situ, where lead may also act as a catalyst if lead is also present along with the second lead iodide.
    Iodine may be introduced into the reaction vessel before, with or after addition of the compound of Formula II and the compound of Formula III when used. Alternatively, iodine may be added in two or more stages, for example, some may be added to the reaction vessel prior to the addition of the compound of formula II and the compound of formula III, with the remainder being the compound of formula II and the formula It can be added while adding the compound of III.
    Lewis acids suitable for use in the present invention are zinc chloride, zinc bromide, zinc iodide, titanium (IV) isopropoxide, chlorotitanium triisopropoxide, titanium tetrachloride, trimethyl borate, boron trifluoride (etherate) Ferric chloride and diethylaluminum chloride.
    Preferred Lewis acids are zinc bromide, zinc iodide, in particular zinc chloride.
    Preference is given to using iodine rather than adding Lewis acids individually.
    Optionally iodine and Lewis acid may be used in the process.
    The reaction may be carried out at -15 ° C to the reflux temperature of the mixture. It is preferable to carry out at -10 ° C to + 30 ° C, most preferably at -10 ° C to + 15 ° C.
    The reaction proceeds almost certainly by forming a type of organozinc derived from the reaction system of zinc with the compound of formula III used as starting material.
    The reaction may be carried out by the following general process.
    Iodine and / or suitable Lewis acid are added to the stirred mixture of zinc, optionally lead and a suitable aprotic organic solvent. The mixture is cooled and a compound of formula (II), a compound of formula (III) and optionally further a solution of iodine in a suitable aprotic organic solvent are added and the mixture is cooled during the addition process. The mixture is further stirred for a short period of time before warming to room temperature. Glacial acetic acid is added followed by water to terminate the reaction, and conventional work-up techniques can be used to isolate the desired product.
    An acid addition salt or base salt of the product is then formed. It is preferable to form acid addition salts, and suitable salts include hydrochloride salt, hydrobromide salt, hydroiodic salt, sulfate salt, nitrate salt, methanesulfonic acid salt, camphorsulfonic acid salt, R-(-)-10- Camphorsulfonic acid salt, (+)-3-bromo-10-camphorsulfonic acid salt, (-)-3-bromo-8-camphorsulfonic acid salt, phosphate salt, para-toluenesulfonic acid salt and Benzene sulfonic acid salts. Hydrochloric acid salts are particularly preferred.
    Compounds of formula (I) prepared by the process of the invention exist in the form of at least four stereoisomers because they contain two or more asymmetric carbon atoms.
    The reaction generally proceeds with high stereoselectivity, with the (2R, 3S / 2S, 3R) enantiomeric pairs of the following compounds (Formula I) predominant:

    Where
    "*" Is an asymmetric carbon atom of the present compound.
    Mixtures of stereoisomers of the compounds of formula (I) or their appropriate salts or derivatives thereof may also be subjected to diastereoisomeric separation by conventional methods (eg, fractional crystallization, chromatography or HPLC). Enantiomers of the compounds of formula (I) can be subjected to HPLC purification of the corresponding racemates with an appropriate chiral support or to the corresponding racemates with a suitable optically active acid (e.g., R-(-)-10-camphorsulfonic acid). The diastereomeric salts formed by reaction can be partitioned by fractional crystallization.
    The process uses the starting materials 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone and 6- (1-bromoethyl)- 3- (4-chloro-5-fluoropyridin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2 from 4-chloro-5-fluoropyrimidine Preference is given to the use in the preparation of, 4-triazol-1-yl) butan-2-ol. If the reaction conditions are carefully controlled, high stereoselectivity can be obtained (eg molar ratio of enantiomeric pairs of 2R, 3S / 2S, 3R and 2R, 3R / 2S, 3S is obtained at 9: 1). In addition, for example, the total isolation yield (in the form of hydrochloride) of all enantiomers is obtained at 65%.
    (2R, 3S / 2S, 3R) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2 The reaction product containing a higher proportion of, 4-triazol-1-yl) butan-2-ol hydrochloride is reduced to give (2R, 3S / 2S, 3R) -2- (2,4-difluoro Phenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol, which can be obtained by European patent (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1-divided by the method disclosed in Japanese Patent Application Laid-Open No. 0440372 (1H-1,2,4-triazol-1-yl) butan-2-ol can be obtained.
    In a further aspect, the present invention provides a process for the preparation of a compound of formula IV or an acid addition salt thereof
    (a) reacting a compound of formula II with a compound of formula IIIA in the presence of zinc, iodine and / or a Lewis acid and an aprotic organic solvent to obtain a compound of formula IA;
    (b) optionally converting a compound of formula (IA) to an acid addition salt thereof;
    (c) reducing the compound of formula (IA) or an acid addition salt thereof to yield a compound of formula (IV); And
    (d) optionally converting the compound of formula IV to its acid addition salt
    Includes:
    Where
    R and R 1 are as defined above for the compound of Formula I,
    R 2 is H or fluoro.
    Formula II

    Where
    R is as defined for the compound of formula IV.
    Where
    X is chloro, bromo or iodo,
    R 1 and R 2 are as defined above for the compound of Formula IV,
    R 3 and R 4 are each independently selected from chloro and bromo, or one of R 3 and R 4 is chloro or bromo, and the other is H.
    Where
    R, R 1 , R 2 , R 3 and R 4 are as defined above for step (a).
    The reaction conditions, including the preferred conditions, used in step (a) are as described above for the preparation of compounds of formula (I). Optionally lead may also be present in step (a).
    In step (c) the reduction may be carried out under any conditions suitable to replace one or more of the R 3 / R 4 group (wherein, R 3 / R 4 groups are chloro or bromo) with hydrogen.
    The reduction may be carried out under a hydrogen atmosphere, using a suitable catalyst (eg palladium on charcoal) under conventional hydrogenation conditions, optionally in the presence of a suitable base (eg sodium acetate) and a suitable solvent (eg ethanol).
    Preferably, the reduction is carried out under transition hydrogenation conditions using a suitable catalyst (eg palladium or rhodium), a suitable hydrogen donor (eg ammonium formate or potassium formate) and a suitable solvent (eg methanol). It is preferable to carry out the reaction under nitrogen atmosphere at the solvent reflux temperature.
    Examples of acid addition salts of step (b) are hydrochloride, nitrate, methanesulfonic acid salt, p-toluenesulfonic acid salt, camphorsulfonic acid salt, R-(-)-10-camphorsulfonic acid salt, (+ ) -3-bromo-10-camphorsulfonic acid salt and (-)-3-bromo-8-camphorsulfonic acid salt. Preferred acid addition salts of step (b) are the hydrochloride salt, methanesulfonic acid salt and p-toluenesulfonic acid salt.
    Preferred acid addition salts of step (d) are the R-(-)-10-camphorsulfonic acid salts, which may be used to cleave the enantiomers of the compound of formula IV. S-(+)-10-camphorsulfonic acid salts may also be produced and used for this purpose.
    In the process for the preparation of the compound of formula IV,
    (i) Preferably, R is phenyl optionally substituted with one to three halo substituents. More preferably, R is phenyl substituted with one or two substituents each independently selected from fluoro and chloro. Even more preferably, R is phenyl substituted with one or two substituents. Most preferably R is 2,4-difluorophenyl.
    (ii) Preferably, R 1 is C 1 -C 4 alkyl. More preferably, R 1 is methyl or ethyl. Most preferably R 1 is methyl.
    (iii) Preferably, X is bromo or iodo. Most preferably, X is bromo.
    (iv) Preferably, R 2 is fluoro.
    (v) Preferably, R 3 is chloro and R 4 is H, R 3 is H and R 4 is chloro, or R 3 and R 4 are both chloro.
    (vi) Preferred compounds of formula IIIA are 6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine, 6- (1-bromoethyl) -4-chloro-5-fluoro Pyrimidine, 6- (1-bromoethyl) -2-chloro-5-fluoropyrimidine and 4- (1-bromoethyl) -6-chloropyrimidine.
    (vii) Preferred compounds of formula (IA) are 3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2, 4-triazol-1-yl) butan-2-ol, 3- (2-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- ( 1H-1,2,4-triazol-1-yl) butan-2-ol, 3- (2,4-dichloro-5-fluoropyrimidin-6-yl) -2- (2,4-di Fluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol and 3- (4-chloropyrimidin-6-yl) -2- (2,4- Difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol, and acid addition salts thereof, in particular hydrochloride, methanesulfonic acid salts and p-toluenesul Phonic acid salts.
    (viii) Preferred compounds of formula IV are 2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazole -1-yl) butan-2-ol and 2- (2,4-difluorophenyl) -3- (pyrimidin-4-yl) -1- (1H-1,2,4-triazole-1 -Yl) butan-2-ol, and acid addition salts thereof, in particular S-(+)-or R-(-)-10-camphorsulfonic acid salts.
    Processes for the preparation of the starting materials used in the process of the invention are conventional, as well as suitable reagents and reaction conditions for the isolation process of the desired product, as well as the existing literature and the preparation examples herein, It is well known to the skilled person.
    The present invention also provides the following novel compounds:
    (i) (2R, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2, 4-triazol-1-yl) butan-2-ol;
    (ii) (2R, 3S / 2S, 3R)-or (2R, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl Acid addition salts of) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol, preferably hydrochloride salts, nitrate salts, methanesulfonic acid salts, p-toluenesulfonic acid salts , Camphorsulfonic acid salts, R-(-)-10-camphorsulfonic acid salts, (+)-3-bromo-10-camphorsulfonic acid salts or (-)-3-bromo-8-camphor Forsulfonic acid salts;
    (iii) 3- (2,4-dichloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazole -1-yl) butan-2-ol or acid addition salts thereof in (2R, 3S / 2S, 3R)-or (2R, 3S) -form or any of these;
    (iv) 3- (2-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazole-1 Acid addition salts of -yl) butan-2-ol or its (2R, 3S / 2S, 3R)-or (2R, 3S) -form or any of these;
    (v) 3- (1-benzyl-5-fluoropyrimidin-6-one-4-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4- Acid addition salts of triazol-1-yl) butan-2-ol or its (2R, 3S / 2S, 3R)-or (2R, 3S) -form or any of these;
    (vi) 3- (4-chloropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butane- Acid addition salts of 2-ols or (2R, 3S / 2S, 3R)-or (2R, 3S) -forms or any of these;
    (vii) 6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine;
    (viii) 4- (1-bromoethyl) -6-chloropyrimidine;
    (ix) 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine;
    (x) 1-benzyl-4- (1-bromoethyl) -5-fluoropyrimidin-6-one;
    (xi) 6- (1-bromoethyl) -2-chloro-5-fluoropyrimidine;
    (xii) 4- (1-bromoethyl) -5-fluoropyrimidine;
    (xiii) ammonium salt of 2-chloro-6-ethyl-5-fluoro-4-hydroxypyrimidine.
    The following examples illustrate the method of the present invention:
    Example 1
    9: 1 * of (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol hydrochloride ( * ratio of in situ)
    A stirred mixture of zinc powder (Britannia Alloys) (9.35 kg), lead (325 mesh, Aldrich) (0.47 kg) and tetrahydrofuran (53 L) was added under nitrogen atmosphere for 3 hours. Heated at reflux. Then the mixture was cooled to 25 ° C. and stirring continued for 16 h. A solution of iodine (7.42 kg) in tetrahydrofuran (21 L) was added for 80 minutes and the temperature was raised to 45 ° C. with addition. The mixture was then cooled to 0-5 C. 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazole-1- in tetrahydrofuran (53 L) while maintaining the reaction temperature below + 5 ° C. during the addition I) a solution of ethanone (6.53 kg) and 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine (see Preparation Example 1) (7.01 kg) was added. The mixture was raised to 25 ° C. and glacial acetic acid (8.84 kg) and water (84 L) were added. The supernatant was decanted to separate solid metal residue, and 60 L of tetrahydrofuran was distilled off under reduced pressure. Ethyl acetate (76 kg) was added and distillation continued to remove 165 L of solvent. The mixture was cooled, extracted with ethyl acetate (2 × 84 L), the extracts collected, washed with a solution of disodium ethylenediaminetetraacetate dihydrate (3.22 kg) in water (161 L), and saturated brine (30 Washed with L).
    The ratio of enantiomeric pairs contained in the organic phase was determined using a 25 cm C18 Dynamax 60 mm reverse phase column, using a mobile phase containing acetonitrile: water in a volume ratio of 65:35 (volume ratio) and a flow rate of 1 ml. Determined by HPLC analysis with / min. The detector was fixed at 254 nm. The molar ratio of 2R, 3S / 2S, 3R (ret. Time = 5.53 min) to 2R, 3R / 2S, 3S (ret. Time = 4.47 min) enantiomeric pairs of organic bases of the title compound was 9: 1.
    The organic layer was concentrated to a volume of 56 L and a solution of hydrogen chloride (1.2 kg) in isopropanol (6 L) was added at 25 ° C. The title compound precipitated out as a solid. It was collected by filtration, washed with ethyl acetate (5 L) and dried (7.89 kg, 65%, melting point: 126-130 ° C).
    Example 2
    10.3: 1 * (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio of in situ)
    A solution of iodine (2.25 g) in tetrahydrofuran (6 mL) was added to a stirred solution of zinc (Britania alloys) (3.00 g) and lead (0.15 g) in tetrahydrofuran (19 mL) under a nitrogen atmosphere at 25 ° C. Added dropwise. The reaction temperature was raised while adding. The mixture was then cooled to 2 ° C. 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone (2.00 g), 6- (1 in tetrahydrofuran (16 mL) A solution of bromoethyl) -4-chloro-5-fluoropyrimidine (Preparation Example 1) (2.84 g) and iodine (0.02 g) was added dropwise over 10 minutes. Cooling was added while adding the reaction temperature to limit the maximum temperature to 16 ° C. It was then further cooled to bring the temperature below +5 ° C. The reaction was stirred at less than +5 ° C for 30 minutes. A sample of the reaction mixture was taken and analyzed by HPLC according to the conditions given in Example 1. The molar ratio of 2R, 3S / 2S, 3R to 2R, 3R / 2S, 3S enantiomeric pairs of the title compound was 10.3: 1. Using an internal reference, the yield of 2R, 3S / 2S, 3R enantiomer pairs was calculated to be 90%.
    Example 3
    11.2: 1 * (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol hydrochloride ( * ratio of isolated products [ratio of same reaction system = 6.7: 1] )
    In tetrahydrofuran (320 mL), zinc powder (Britania alloys) (37.9 g), lead (1.9 g) and lead chloride (16.2 g) were stirred at 2 ° C under a nitrogen atmosphere. 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone (26.6 g) and 6- (1 in tetrahydrofuran (215 mL) A solution of bromoethyl) -4-chloro-5-fluoropyrimidine (see Preparation Example 1) (40 g) was added dropwise over 5 minutes. While cooling, the reaction temperature was kept below 12 ° C. The reaction was stirred for 3 hours below + 10 ° C. and stirred at ambient temperature overnight. The termination of the reaction was confirmed by HPLC using the conditions set forth in Example 1. The analysis showed a molar ratio of 2R, 3S / 2S, 3R to 2R, 3R / 2S, 3S enantiomeric pairs of free base of the title compound as 6.7: 1. Glacial acetic acid (8 g) and water (400 mL) were then added while maintaining the reaction temperature below 25 ° C. and the mixture was stirred for 15 minutes. The supernatant was decanted to remove solid metal residues. Using saturated aqueous sodium carbonate solution (600 mL), the mixture was basified to pH 10 and adjusted back to pH 8.0 with 5M aqueous hydrochloric acid solution (15 mL). The solid was filtered off and the tetrahydrofuran was removed by distillation under reduced pressure. The mixture was extracted with ethyl acetate (2 × 400 mL). The combined organic phases were washed with water (400 mL), washed with 2% (w / v) disodium ethylenediaminetetraacetic acid solution in water (800 mL) and with water (400 mL). The ethyl acetate layer was concentrated to oil. The oil was dissolved in ethyl acetate (225 mL) and a 5.75 M solution of hydrogen chloride in isopropanol (20 mL) was added. The slurry was granulated at 20 ° C. for 1 hour and granulated at 0 ° C. for 1 hour. The crude title compound was isolated by filtration and dried at 50 ° C. under reduced pressure (39.9 g). HPLC analysis according to the conditions set forth in Example 1 showed a 93.9% by weight ratio of the title compound in the crude product.
    Example 4
    10.2: 1 * (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio of in situ)
    A mixture of zinc powder (Britania alloys) (3.00 g) and tetrahydrofuran (20 mL) was stirred overnight at room temperature, then a solution of iodine (2.27 g) in tetrahydrofuran (6 mL) was added dropwise over 3 minutes. It was. The reaction temperature was raised to about 45 ° C. while adding, cooled to 5-10 ° C., and then 1- (2,4-difluorophenyl) -2- (1H-1,2) in tetrahydrofuran (16 mL). A solution of, 4-triazol-1-yl) ethanone (2.00 g) and 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine (see Preparation Example 1) (2.9 g) Add for 40 minutes (using the same dropping funnel used for the addition of iodine).
    After stirring for 2 hours, a sample of the reaction mixture was taken and analyzed by HPLC using the conditions set forth in Example 1. By comparison with the control reference (see Example 1), the reaction mixture was found to contain enantiomeric pairs of the title compound with a molar ratio of 2R, 3S / 2S, 3R to 2R, 3R / 2S, 3S of 10.2: 1. . Total yield was calculated to be about 72%.
    Further measurement after 1 hour showed little difference from the above state. The reaction was terminated in this state and no longer evaluated.
    Example 5
    9.4: 1 * (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio of in situ)
    A solution of iodine (2.04 g) in tetrahydrofuran (6 mL) was added to a stirred slurry of zinc (Britania alloys) (3.00 g) in tetrahydrofuran (19 mL) under a nitrogen atmosphere at 25 ° C. The reaction temperature was raised while adding. The mixture was then cooled to 2 ° C. 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) in tetrahydrofuran (16 mL) while cooling to keep the temperature below + 5 ° C. A solution of ethanone (2.00 g), 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine (see preparation example 1) (3.00 g) and iodine (0.23 g) for 10 minutes Added dropwise. The reaction mixture was stirred at less than + 5 ° C. for 30 minutes. A sample of the reaction mixture was taken and analyzed by HPLC according to the conditions given in Example 1. The analysis showed a molar ratio of enantiomeric pairs of 2R, 3S / 2S, 3R to 2R, 3R / 2S, 3S of the title compound of 9.4: 1. Using an internal reference, the yield of 2R, 3S / 2S, 3R enantiomer pairs was calculated to be 77%.
    Example 6
    10.2: 1 * (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio of in situ)
    A solution of iodine (2.20 g) in tetrahydrofuran (6 mL) was added dropwise to a stirred slurry of zinc (Britania alloys) (3.00 g) in tetrahydrofuran (19 mL) under a nitrogen atmosphere at 25 ° C. The reaction temperature was raised while adding. The mixture was then cooled to 2 ° C. 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone (2.00) and 6- in tetrahydrofuran (16 mL) for 10 minutes. (1-Bromoethyl) -4-chloro-5-fluoropyrimidine (see Preparation Example 1) (2.84 g) was added dropwise for 10 minutes. In addition, a solution of iodine (0.07 g) in tetrahydrofuran (4 mL) was added during the first 2 minutes of this addition process. Cool to maintain reaction temperature below +5 ° C. The reaction was stirred at less than + 5 ° C. for 30 minutes. A sample of the reaction mixture was taken and analyzed by HPLC according to the conditions given in Example 1. The analysis showed that the molar ratio of enantiomeric pairs of 2R, 3S / 2S, 3R to 2R, 3R / 2S, 3S of the title compound was 10.2: 1. Using an internal reference, the yield of 2R, 3S / 2S, 3R enantiomeric pairs was 87%.
    Example 7
    64: 1 * of (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2, 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol hydrochloride ( * ratio in isolated product)
    A solution of iodine (20.52 g) in tetrahydrofuran (65 mL) was added dropwise to a stirred slurry of zinc powder (28.6 g) in tetrahydrofuran (160 mL) under a nitrogen atmosphere at 20 ° C. The reaction temperature was raised to 25 ° C. The mixture was then cooled to 0-5 ° C. 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazole-) in tetrahydrofuran (160 mL) while cooling to maintain the reaction temperature at 0 ° C to + 5 ° C. A solution of 1-yl) ethanone (20.0 g), 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine (see Preparation Example 1) (23.6 g) and iodine (2.28 g) Add dropwise for 75 minutes. The reaction temperature was stirred at less than + 5 ° C. for 30 minutes. The termination of the reaction was confirmed by HPLC using the conditions set forth in Example 1. The analysis showed that the stoichiometric yield of the 2R, 3S / 2S, 3R enantiomer pair was 88%. Glacial acetic acid (5.4 mL) and water (260 mL) were then added while maintaining the reaction temperature below 25 ° C. The supernatant was decanted to remove solid metal residues. The mixture was basified to pH 10 with saturated aqueous sodium carbonate solution (180 mL) and adjusted to pH 8.0 with 5 M aqueous hydrochloric acid solution. The solid was filtered off and the tetrahydrofuran was removed by distillation under reduced pressure. Ethyl acetate (260 mL) was added and the mixture was stirred for 10 minutes. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (86 mL). The organic phases were combined and washed with 2% (w / v) disodium ethylenediaminetetraacetic acid solution in water (286 mL), water (139 mL) and saturated brine (52 mL). The ethyl acetate layer was concentrated to a volume of 150 ml. A solution of sulfosalicylic acid (1.86 g) in isopropanol (5 mL) was added and the slurry was granulated at 20 ° C. for 2 hours. The solid was filtered off and washed with ethyl acetate (2 × 3 mL). 6M solution of hydrogen chloride in isopropanol (molar ratio of 1.1 to amount of product in filtrate and 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone) Was added to the filtrate, the slurry was granulated at 25 ° C. for 2 hours, and further granulated at 0-2 ° C. for 1 hour. The crude title compound was isolated by filtration, washed with ethyl acetate (20 mL) and dried at 50 ° C. under reduced pressure. Mass yield was 30 g. HPLC analysis according to the conditions set forth in Example 1 showed that the product contained 75.7% (stoichiometric yield) of the enantiomeric pairs of 2R, 3S / 2S, 3R of the title compound.
    Example 8
    5.5: 1 * of (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (2,4-dichloro-5-fluoropyrimidin-6-yl) -2- ( 2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio of in situ)
    A stirred mixture of zinc powder (Britania alloys) (78.6 g), lead powder (Aldrich) (3.9 g) and tetrahydrofuran (450 mL) was kept at 20 ° C. for 17 hours and then tetrahydrofuran ( 450 ml) was treated with a solution of iodine (153 g) and cooled to maintain the temperature below 45 ° C. The mixture is then cooled to 30 ° C. and 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) in tetrahydrofuran (300 mL). Ethanone (134.7 g) and 6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine (see Preparation Example 3) (82.4 g) were added and the temperature was 3 to -5 ° C. Was maintained. The mixture was warmed to 30 ° C. and maintained at this temperature for 2 hours, then the reaction was terminated with glacial acetic acid (150 mL) and water (750 mL). The supernatant was decanted from the metal residue and concentrated under reduced pressure to remove tetrahydrofuran. Ethyl acetate (2.5 L) was added and the mixture was basified by addition of saturated aqueous sodium carbonate solution (1.5 L). The mixture was granulated at 20 ° C. for 30 minutes and the precipitated zinc carbonate was filtered off. The organic phase in the filtrate was separated, washed with water (2 x 2.0 L) and concentrated under reduced pressure. The resulting solution was treated with a solution of 5-sulfosalicylic acid dihydrate (107.5 g) in isopropanol (215 mL). After granulation at 20 ° C. for 1 hour, precipitated 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone sulfosalicylic acid salt It was here. The filtrate was washed with 5% (w / v) disodium ethylenediaminetetraacetate dihydrate aqueous solution (2 x 500 mL), water (500 mL) and then concentrated under reduced pressure to afford the crude product as a syrup ( 123.8 g).
    HPLC analysis using the conditions set forth in Example 1 showed that the product showed 2R, 3S / 2S, 3R (ret. Time = 5.6 min) versus 2R, 3R / 2S, 3S (ret. Time = 7.1 min) of the title compound. It was found to contain isomeric pairs in a molar ratio of 5.5: 1.
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.06 (d, 3H), 3.95 (q, 1H), 4.34 (d, 1H), 4.70 (d, 1H), 5.55 (s, br., 1H ), 6.65-6.80 (m, 2H), 7.45-7.56 (m, 1H), 7.55 (s, 1H), 7.93 (s, 1H) ppm.
    Example 9
    9.2: 1 * (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (1-benzyl-5-fluoropyrimidin-6-one-4-yl) -2 -(2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio in isolated product)
    A stirred mixture of zinc powder (Pasminco) (573 mg), lead powder (29 mg) and tetrahydrofuran (6 mL) was kept at room temperature for 18 hours and then in tetrahydrofuran (2 mL). A solution of iodine (370 mg) was added. Then, 1- (2,4-difluorophenyl) -2- (1H-1,2,4-triazol-1-yl) ethanone (653 mg) in tetrahydrofuran (7 mL) for 10 minutes. ) And 1-benzyl-4- (1-bromoethyl) -5-fluoropyrimidin-6-one (see Preparation Example 5) (1.00 g) was added dropwise to the mixture. The reaction was heated to about 40 ° C. for 1 hour, then cooled and the reaction was terminated with glacial acetic acid (1 mL) and water (10 mL). The mixture was partitioned between water and ethyl acetate, the organic layer was separated, washed with aqueous potassium bicarbonate solution and then brine, then dried over MgSO 4 and concentrated under reduced pressure. The residue was chromatographed on silica gel eluting with hexanes: ethyl acetate (gradient of solvent used; 4: 1 to 1: 1 to 0: 1) to give the product as a white solid (519 mg, 39%).
    HPLC analysis according to the conditions given in Example 1 showed that the product was a mirror image of 2R, 3S / 2S, 3R (ret. Time = 3.78 min) versus 2R, 3R / 2S, 3S (ret. Time = 5.28 min) of the title compound. It was found to contain isomeric pairs in a molar ratio of 9.2: 1.
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.02 (d, 3H), 3.91 (q, 1H), 4.30 (d, 1H), 4.78 (d, 1H), 5.12 (d, 1H), 5.19 (d, 1H), 5.95 (s, 1H), 6.72-6.86 (m, 2H), 7.30-7.56 (m, 7H), 7.89 (s, 1H), 8.00 (s, 1H) ppm.
    Example 10
    (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloropyrimidin-6-yl) -2- (2,4-difluoro of 12.5: 1 * Phenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol ( * ratio of in situ)
    A mixture of zinc powder (Britania alloys) (249 g), lead powder (12.3 g) and tetrahydrofuran (760 mL) was stirred overnight at room temperature, then iodine (203.4 g) in tetrahydrofuran (650 mL) Solution was added dropwise. The reaction temperature was raised to about 45 ° C. during the addition. Then cool to 5-10 ° C. and maintain 1- (2,4-difluorophenyl) -2- (1H-1,2,4) in tetrahydrofuran (1600 mL) while keeping the temperature below 55 ° C. -Triazol-1-yl) ethanone (199 g), 4- (1-bromoethyl) -6-chloropyrimidine (293 g of crude product of Preparation 6 is calculated to contain 217 g of the pyrimidine Solution) and iodine (22.6 g) were added for 30 minutes. After 1 hour, a sample of the reaction mixture was taken and analyzed by HPLC using the conditions set forth in Example 1. The molar ratio of enantiomeric pairs of 2R, 3S / 2S, 3R (ret. Time = 4.23 minutes) to 2R, 3R / 2S, 3S (ret. Time = 3.4 minutes) was determined to be 12.5: 1.
    The reaction mixture was cooled to 20 ° C. and the reaction was terminated by addition of glacial acetic acid (56 g) and water (180 mL). Filtration removed the zinc residue and the mixture was treated with aqueous sodium carbonate solution until pH 10. The pH was then lowered to 7.5 using dilute aqueous hydrochloric acid solution and the precipitated zinc carbonate was filtered off. The solution was concentrated under reduced pressure to remove most of the tetrahydrofuran and extracted with dichloromethane (2 x 500 mL) to give an aqueous slurry. The organic phases were combined and washed with 5% (w / w) of disodium ethylenediaminetetraacetic acid aqueous solution (2 x 500 mL). The organic phase was concentrated under reduced pressure and the residue was crystallized from isopropyl alcohol (2.5 L) and filtered to collect solids. After drying at 50 ° C. under reduced pressure, the product (140 g) was analyzed by HPLC and found to contain 91% by weight of 2R, 3S / 2S, 3R enantiomeric pairs of the title compound.
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.1 (d, 3H), 3.65 (q, 1H), 4.15 (d, 1H), 4.8 (d, 1H), 6.15 (s, 1H), 6.8 ( m, 2H), 7.5 (s, 1H), 7.55 (m, 1H), 7.65 (s, 1H), 7.9 (s, 1H), 8.9 (s, 1H) ppm.
    The following preparations illustrate the further treatment of the specific compounds of these examples, along with the preparation of the particular starting materials used in the foregoing examples.
    Preparation Example 1
    6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine
    (i) 2,4-dichloro-5-fluoropyrimidine
    A stirred mixture of 5-fluorouracil (111.5 kg) and phosphorus oxychloride (394.6 kg) was heated to 95 ° C. and N, N-dimethylaniline (207 kg) was added for 1 hour, during which the exothermic reaction occurred. woke up. The mixture was kept at 95 ° C. for 15 hours, then cooled to room temperature, and carefully placed in ice cold 3N hydrochloric acid solution (450 L) for 4 hours while maintaining the temperature below 30 ° C. to terminate the reaction. The mixture was extracted with dichloromethane (2 x 390 L) and the combined extracts were washed with water (280 L) until the pH of the aqueous wash was 7 and concentrated under reduced pressure. The residue was taken up in dimethoxyethane (190 L) and the solution of the product was used directly in the next step.
    1 H-NMR (300 MHz, CDCl 3 ): δ = 8.5 (s, 1H) ppm.
    (ii) 2,4-dichloro-6-ethyl-5-fluoropyrimidine
    A solution of bromoethane (54.3 kg) in tetrahydrofuran (53 L) was added to a stirred solution of magnesium turning (12.1 kg) in tetrahydrofuran (161 L) while maintaining the reaction temperature below 50 ° C. Added. The Grignard reagent solution was cooled to 0 ° C. and a solution of the compound of step (i) (56 kg) in dimethoxyethane (170 L) was added while maintaining the reaction temperature below 15 ° C. The reaction was stirred at 15 ° C. for 1 hour and cooled to 0 ° C. A solution of triethylamine (34 kg) in tetrahydrofuran (70 L) was added while maintaining the reaction temperature at about 5 ° C. and iodine (85 L) in tetrahydrofuran (256 L) while maintaining the reaction temperature below 15 ° C. Kg) solution was added. The reaction was then terminated with water (840 L) while maintaining the reaction temperature below 25 ° C. The pH was adjusted to 1 with 5N aqueous hydrochloric acid solution (50 L) and the mixture was extracted with toluene (extracted with 1 x 490 L and then with 1 x 210 L). The combined organic layers were washed with 2% (w / w) aqueous sodium metabissulphite solution (700 L), then water (700 L) was added and the remaining tetrahydrofuran was distilled off under reduced pressure. The mixture was cooled and the organic layer was separated, washed with water (425 L) and then concentrated under reduced pressure to give the product as an oil (50 kg).
    (iii) 2-chloro-6-ethyl-5-fluoro-4-hydroxypyrimidine ammonium salt
    The mixture of compound (40 kg) and water (10 kg) of step (ii) was raised to 90 ° C. and 4N aqueous sodium hydroxide solution (127 L) was added. Continue heating to 80 ° C. for 30 minutes, then cool the mixture to 25 ° C. The mixture was washed with toluene (124 L) and the aqueous layer was separated and dichloromethane (162 L) was added. Concentrated hydrochloric acid was added until the mixture reached pH 1. The organic layer was separated and the aqueous layer was extracted with dichloromethane (162 L). The organic layers were combined and treated with activated carbon (trade name Norit) (8.8 kg). The solution was filtered and treated with concentrated ammonium solution until pH 9. The product precipitated out as a solid which was collected by filtration (34 kg, melting point: 125-131 ° C.).
    (iv) 6-ethyl-5-fluoro-4-hydroxypyrimidine
    To a mixture of compound (34 kg), ethanol (170 L) and water (5 kg) of step (iii) add 5% (w / w) palladium on carbon (water content 50% w / w) (3.4 kg) The mixture was hydrogenated at 50 ° C., 345 kPa (50 psi) until the reaction was complete. Water (10.5 L) was added and the catalyst was filtered off. The filtrate was concentrated to a small volume under reduced pressure and extracted with dichloromethane (2 x 58 L). The organic extracts were combined and concentrated under reduced pressure and toluene (150 L) was added. The mixture was concentrated under reduced pressure until the volume reached 50 L, toluene (50 L) was added and cooled to 4 ° C. for 4 h. The precipitated product was collected by filtration, washed with toluene (10 L) and dried (yield: 20 kg, melting point: 112-4 ° C).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.25 (m, 3H), 2.73 (m, 2H), 8.00 (s, 1H) ppm.
    (v) 4-chloro-6-ethyl-5-fluoropyrimidine
    To the mixture of compound (40 kg), dichloromethane (120 L) and triethylamine (28.4 g) in step (iv) was added 3 phosphorus oxychloride (47.2 kg) while maintaining the reaction temperature below 40 ° C. Add slowly over time. The mixture was heated to reflux for 5 hours, cooled to 25 ° C., and carefully placed in 3N aqueous hydrochloric acid solution (176 L) while maintaining the temperature below 20 ° C. to terminate the reaction. The layers were separated and the aqueous phase was extracted with dichloromethane (50 L) and the organic phases were combined and washed with water (50 L). The organic phase was concentrated under reduced pressure to give the product as an oil (40.69 kg).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.30 (t, 3H), 2.87 (q, 2H), 8.65 (s, 1H) ppm.
    (vi) 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine
    A stirred mixture of compound (38.5 kg), azoisobutyronitrile (AIBN) (1.92 kg), N-bromosuccinimide (49 kg) and dichloromethane (198 L) of step (v) was purged with nitrogen for 12 hours. Heated under reflux under atmosphere. The mixture was cooled to 25 ° C. and water (239 L) was added. The layers were separated and the aqueous layer was extracted with dichloromethane (120 L). The organic phases were combined and washed with a solution of sodium metabisulfite (22.8 kg) in water (239 L) and washed with water (239 L). The organic phase was concentrated under reduced pressure, toluene (240 L) was added and the resulting solution was concentrated under reduced pressure to give the product as an oil (61.7 kg).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 2.08 (d, 3H), 5.35 (q, 1H), 8.80 (s, 1H) ppm.
    Preparation Example 2
    (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazole-1- I) butan-2-ol
    (i) (2R, 3S / 2S, 3R) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2, 4-triazol-1-yl) butan-2-ol
    The pH of the stirred mixture of product (26.5 kg), dichloromethane (400 L) and water (184 L) obtained by the method of Example 1 using 40% (w / w) aqueous sodium hydroxide solution (10 L) 11 was adjusted. The organic phase was separated, washed with a solution of disodium ethylenediaminetetraacetate dihydrate (8.74 kg) in water (183.5 L), washed with water (184 kg) and concentrated to oil under reduced pressure. To this was added ethanol (134 L), sodium acetate (8 kg) and 5% (w / w) palladium on carbon (water content 50% w / w), and the mixture was stirred at 25 ° C., 103 until the reaction was complete. Hydrogenated at kPa (15 psi). The catalyst was filtered off and the filtrate was concentrated until the volume reached 51 L. Dichloromethane (152 L) and water were added and the pH was adjusted to 11 using 40% (w / w) aqueous sodium hydroxide solution. The layers were separated and the aqueous layer was extracted with dichloromethane (61 L). The organic layers were combined, washed with water (61 L), concentrated under reduced pressure, isopropanol (70 L) was added, and then concentrated to 62 L. The mixture was granulated at 20 ° C. for 3 hours, filtered and washed with isopropanol (2 × 5 L) and dried to give the title compound as the main enantiomeric pair in the product (19 kg, melting point: 127 ° C.). ).
    (ii) (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazole -1-yl) butan-2-ol
    To a solution of the compound of step (i) (18.93 kg) in acetone (426 L) is added a solution of R-(-)-10-camphorsulfonic acid (12.57 kg) in methanol (142 L) and a homogeneous solution The mixture was heated at reflux until it was obtained. The solution was cooled to 20 ° C. and granulated overnight. The solid was collected by filtration, washed with acetone (9.35 kg) and dried to give (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl). -1- (1H-1,2,4-triazol-1-yl) butan-2-ol R-(-)-10-camphorsulfonic acid salt was obtained as a white solid (12.3 kg).
    The camphorsulfonic acid salt (12.3 kg) was dissolved in dichloromethane (61.5 L) and water (61.5 L) and the pH was adjusted to 11 using 40% (w / w) aqueous sodium hydroxide solution (2.5 L). Adjusted. The layers were separated and the aqueous layer was extracted with dichloromethane (14 L). The combined organic extracts were washed with water (3 x 45 L), filtered and distilled under reduced pressure to remove the solvent. Isopropanol (30 L) was added and distillation continued until the volume reached 22 L. The mixture was cooled to 0 ° C. and granulated for 2 hours. The product was collected by filtration and isopropanol (2 × 4 L) was washed to give the title compound as a white solid (7.6 kg).
    Preparation Example 3
    6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine
    (i) 2,4-dichloro-6-ethyl-5-fluoropyrimidine
    A solution of bromoethane (407 g) in tetrahydrofuran (1.04 L) was added to a stirred mixture of magnesium turning agent (90.4 kg) in tetrahydrofuran (1.04 L) while maintaining the reaction temperature at 35-40 ° C. . The solution of Grignard reagent was stirred at 20 ° C. for 30 minutes, cooled to 0 ° C., and the compound of Preparation Example 1 (i) in dimethoxyethane (600 mL) while maintaining the reaction temperature below 15 ° C. (420 g) Solution was added. The mixture was stirred at 15 ° C. for 1 hour and then cooled to 0 ° C. While maintaining the temperature below 15 ° C., a solution of triethylamine (254 g) in tetrahydrofuran (510 mL) was added at 5 ° C., and a solution of iodine (632 g) in tetrahydrofuran (1.92 L) was added. It was. The reaction was terminated with water (6 L) while maintaining the temperature below 25 ° C. The mixture was acidified with 5N aqueous hydrochloric acid solution to pH 1 and extracted with ethyl acetate (2 × 6 L). The organic layers were combined and washed with 10% (w / v) aqueous sodium metabisulfite solution (12 L). Water (4 L) was added and most of the organic solvent was removed by evaporation under reduced pressure. The layers were separated and the aqueous layer was extracted with ethyl acetate (2 L). The combined organic extracts were treated with glacial acetic acid (400 mL) and concentrated at 80 ° C. under reduced pressure. The mixture was cooled to 20 ° C. and the oil was partitioned between dichloromethane (3 L) and 1N aqueous sodium hydroxide solution (3 L). The organic phase was separated, washed with water (3.0 L) and concentrated under reduced pressure to give the product as an oil (402 g).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.33 (t, 3H), 2.87 (dq, 2H) ppm.
    (ii) 6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine
    A mixture of compound (400 g), N-bromosuccinimide (730 g), azoisobutyronitrile (33.7 g), bromine (65.5 g) and water (6.4 L) of step (i) was added for 5 hours. Heated at 80-85 ° C. Additional N-bromosuccinimide (183 g) was added and heating continued for 2 hours, followed by additional azoisobutyronitrile (33.7 g). After heating at 85 ° C. for 2 hours, additional azoisobutyronitrile (33.7 g) was added and heating continued for 3 hours. The reaction mixture was cooled down, diluted with water (4 L) and extracted with dichloromethane (2 x 3 L). The organic extracts were combined and washed with a solution of sodium metabisulfate (600 g) in water (2.5 L), followed by water (3 L). The solvent was removed by evaporation under reduced pressure, toluene (1.0 L) was added and the solution was concentrated under reduced pressure to give the product as an oil (534 g).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 2.05 (d, 3H), 5.06 (q, 1H) ppm.
    Preparation Example 4
    (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazole-1- I) butan-2-ol
    (i) (2R, 3S / 2S, 3R) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2, 4-triazol-1-yl) butan-2-ol
    Product obtained by the method of example 8 (123.8 g), sodium acetate (27.4 g), 5% (w / w) palladium on carbon (water content 50% w / w) (18.6 g) and ethanol (1.24 L) ) Was stirred at 50 ° C., 345 kPa (50 psi) for 19 hours. The reaction was cooled to 25 ° C., the catalyst was filtered off and washed with ethanol (100 mL). The filtrate was concentrated to dryness under reduced pressure and the residue was partitioned between dichloromethane (1.0 L) and 10% (w / v) aqueous potassium bicarbonate solution (1.0 L). The organic layer was separated, washed with water, evaporated under reduced pressure and dried to afford the title compound as the main enantiomeric pair in the product. This was used directly in the next step.
    1 H-NMR (300 MHz, d 6 -DMSO): δ = 1.10 (d, 3H), 3.90 (q, 1H), 4.33 (d, 1H), 4.80 (d, 1H), 6.87-6.93 (m, 1H ), 7.10-7.20 (m, 1H), 7.21-7.34 (m, 1H), 7.60 (s, 1H), 8.21 (s, 1H), 8.82 (s, 1H), 9.02 (s, 1H) ppm.
    (ii) (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazole -1-yl) butan-2-ol
    The product of step (i) was dissolved in acetone (383 mL) and R-(-)-camphor-10-sulfonic acid (42.1 g) in acetone (300 mL) was added. The mixture was granulated at 20 ° C. for 18 hours and cooled to 0 ° C. for 1 hour. The solid was filtered off, washed with cold acetone (100 mL) and dried to afford the crude camphorsulfonate product (35.4 g).
    HPLC analysis (25 cm x 4.6 mm C18 Dynamax 60 mm reverse phase column, mobile phase; acetonitrile: water (volume basis) = 65:35, flow rate; 1 ml / min) as a result, the chemical purity of the material was 91%, 2R The molar ratio of, 3S- to 2S, 3R-enantiomer pairs was 63:37.
    This partially partitioned salt (34 g) was dissolved in a mixture of methanol (110 mL) and acetone (329 mL) and heated while refluxing. The solution was cooled to 20 ° C. and granulated overnight. The solid was collected by filtration, washed with acetone (50 mL) and dried to afford (2R, 3S) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl ) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol R-(-)-camphor-10-sulfonate was obtained as a white solid (17.1 g, Melting point: 187 ° C.).
    HPLC analysis showed that the optical purity of this material was 100%.
    This salt (17 g) was partitioned between dichloromethane (85 mL) and water (85 mL) and adjusted to pH 11 by addition of 40% (w / w) aqueous sodium hydroxide solution. The layers were separated and the aqueous phase was extracted with dichloromethane (20 mL). The combined organic extracts were washed with water (2 x 80 mL), filtered and the solvent was removed by evaporation under reduced pressure. Isopropanol (26 mL) was added and the solution was cooled to 0 ° C. and granulated for 1 hour. The solid was collected by filtration, washed with cold isopropanol (5 mL) and dried at 50 ° C. under reduced pressure to give the product (8.4 g, melting point: 133 ° C.).
    1 H-NMR (300 MHz, d 6 -DMSO): δ = 1.10 (d, 3H), 3.90 (q, 1H), 4.33 (d, 1H), 4.80 (d, 1H), 6.87-6.93 (m, 1H ), 7.10-7.20 (m, 1H), 7.21-7.34 (m, 1H), 7.60 (s, 1H), 8.21 (s, 1H), 8.82 (s, 1H), 9.02 (s, 1H) ppm.
    Preparation Example 5
    1-benzyl-4- (1-bromoethyl) -5-fluoropyrimidin-6-one
    (i) 1-benzyl-4-ethyl-5-fluoropyrimidin-6-one
    Sodium hydride (60% (w / w) in oil, 928 mg) was triturated with hexanes and then dimethylformamide (30 mL) was added. To this mixture was added compound (3 g) of Preparation Example 1 (iv), and after foaming, benzyl bromide (2.51 mL) was added. The mixture was stirred for 1 h and then quenched with water. The mixture was partitioned between diethyl ether and water, the ether layer was separated, washed successively with dilute sodium hydroxide solution, brine and water and then concentrated under reduced pressure to afford the desired product as white crystals (4.04 g, LRMS m / z = 232.9 (m) + ).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.22 (t, 3H), 2.63 (dq, 2H), 5.14 (s, 2H), 7.32-7.40 (m, 5H), 7.93 (s, 1H) ppm .
    (ii) 1-benzyl-4- (1-bromoethyl) -5-fluoropyrimid-6-one
    A mixture of compound (2 g), N-bromosuccinimide (1.76 g), azoisobutyronitrile (71 mg) and dichloromethane (20 mL) of Preparation Example 5 (i) was added under nitrogen atmosphere for 20 hours. Heated to reflux. The reaction mixture was cooled and washed successively with dilute aqueous sodium metabisulfite solution, water and brine, then dried over MgSO 4 and concentrated under reduced pressure. The residue was eluted with ethyl acetate: hexanes (1: 7 by volume) on silica gel to give the product as a white syrup (1.60 g, LRMS m / z = 310.9 / 312.9 (m) + ).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.94 (d, 3H), 5.07 (d, 1H), 5.17 (d, 1H), 5.30 (q, 1H), 7.30-7.41 (m, 5H), 8.00 (s, 1 H) ppm.
    Preparation Example 6
    4- (1-bromoethyl) -6-chloropyrimidine
    (i) 4-ethyl-6-hydroxypyrimidine
    At 20 ° C. formamidine acetate (500 g) and methyl 3-oxopentanoate (500 g) were added to a solution of sodium methoxide (500 g) in methanol (4 L) and the mixture was stirred for 15 hours. . Water (1 L) and acetic acid (500 mL) were added to reach pH 7. The solvent was removed by evaporation under reduced pressure, and the aqueous residue was washed with water (1 L) and extracted with methyl ethyl ketone (4 x 2.5 L). The organic phases were combined and concentrated by evaporation under reduced pressure to give an orange syrup. The syrup was dissolved in ethyl acetate (1 L) and the solution stirred for 15 hours to give a solid. The solid was collected by filtration, washed with ethyl acetate (200 mL, 10 ° C.) and dried at 50 ° C. under reduced pressure to give the title compound (183 g). After the mother liquor was concentrated under reduced pressure, diethyl ether (3 L) was added to give a solid. This solid was collected by filtration, washed with tert-butyl methyl ether (200 mL) and dried at 50 ° C. under reduced pressure to give the title compound secondary (195 g). The total yield of the title compound is about 79%.
    1 H-NMR (300 MHz, D 2 O): δ = 1.02-1.12 (m, 3H), 1.89 (s, 1H), 2.41-2.55 (m, 2H), 6.21 (s, 1H), 8.16 (s, 1H) ppm.
    (ii) 4-chloro-6-ethylpyrimidine
    The product of Preparation Example 6 (i) (348 g) was slurried in dichloromethane (2.5 L) and triethylamine (284 g) was added. Phosphorous oxychloride (473 g) was added to the mixture, and the exothermic reaction brought the temperature of the reaction mixture to reflux. The reflux temperature was maintained for 4 hours, then the reaction mixture was cooled to 20 ° C. and cooled (maintained at about 10 ° C.) in 1N aqueous hydrochloric acid solution (2.2 L) to terminate the reaction. After separation of the organic phase, the aqueous phase was extracted with dichloromethane (1 L). The organic phases were combined and washed with water (2 × 3 L). The solution was concentrated under reduced pressure to give the product as a dark oil (272 g, 80% purity according to 1 H-NMR).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.31 (t, 3H), 2.80 (q, 2H), 7.23 (s, 1H), 8.88 (s, 1H) ppm.
    (iii) 4- (1-bromoethyl) -6-chloropyrimidine
    The product (212 g) of Preparation Example 6 (ii) was dissolved in dichloromethane (2.1 L). N-bromosuccinimide (305.3 g) and azoisobutyronitrile (10.6 g) were added and the mixture was heated at reflux for 24 hours. Water (500 mL) was added and heating continued at reflux for an additional hour before cooling the mixture to 20 ° C. The organic phase was separated, washed with aqueous sodium metabisulfide solution (1 L) and then with water (1 L). Drying the organic phase with magnesium sulfate (20 g) and evaporating under reduced pressure yielded the crude title compound as dark oil (312 g, about 74% pure by calculation of 1 H-NMR), which is the example Used at 10.
    1 H-NMR (300 MHz, CDCl 3 ): δ = 2.03 (d, 3H), 5.04 (q, 1H), 7.51 (s, 1H), 8.95 (s, 1H) ppm.
    Preparation Example 7
    (2R, 3S / 2S, 3R) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-tria Zol-1-yl) butan-2-ol R-(-)-10-camphorsulfonate
    119: 1 (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4 -Difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol hydrochloride salt (40 g) was dissolved in methanol (360 mL). 10% (w / w) of palladium on carbon (water content 50% w / w) (5.6 g) and ammonium formate (24 g) were added under nitrogen atmosphere. The reaction mixture was heated to reflux for 2 hours and cooled to 25 ° C. The catalyst was filtered off and washed with methanol (120 mL). The filtrate was 2 minutes (2 x about 245 mL).
    One portion was concentrated under reduced pressure and the residue was dissolved in methylene chloride (95 mL) and water (95 mL) and stirred for 15 minutes. The organic phase was separated, washed with water (2 × 60 mL) and concentrated to oil under reduced pressure. Isopropanol (100 mL) was added and the mixture was concentrated under reduced pressure. Isopropanol (90 mL) was added and the mixture was heated to 55 ° C. to give a solution. To this solution was added a solution of R-(-)-10-camphorsulfonic acid in isopropanol (21.5 mL). The resulting slurry was cooled to 25 ° C., granulated for 1 hour and then cooled to 0 ° C. and granulated for an additional 2 hours. The product was isolated by filtration, washed with cold isopropanol (2 x 20 mL) and dried under reduced pressure to give the title compound (23.7 g). HPLC analysis using the conditions set forth in Example 1 showed the product to be the pure title compound.
    Preparation Example 8
    (2R, 3S / 2S, 3R) -2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-tria Zol-1-yl) butan-2-ol
    16.36: 1 (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4 -Difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol hydrochloride (1.7 kg with solvent; of (2R, 3S / 2S, 3R) 1.08 kg) was added to methylene chloride (8.5 L) and water (8.5 L) with stirring to calculate the portion of the enantiomeric pair. The mixture was basified to pH 11 with 40% aqueous sodium hydroxide solution and the layers separated. The aqueous phase was extracted with methylene chloride (1.7 L). The organic extracts were combined, washed with a solution of disodium ethylenediaminetetraacetic acid dihydrate (425 g) in water (8.5 L), followed by water (2 × 5 L). The methylene chloride solution was 2 minutes in different amounts. Both parts were concentrated under reduced pressure to give an oil ( 1 H-NMR calculation considering solvent, containing 198 g and 980 g, respectively). HPLC analysis using the conditions set forth in Example 1 showed that the oil was (2R, 3S / 2S, 3R) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2 , 4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol was found to contain 76% and 69% by weight, respectively.
    A sample of "980 g" was dissolved in methanol (10 L) and 10% (w / w) palladium on carbon (water content 50% w / w) (Johnson Matthey type 87L) under nitrogen atmosphere ( 69 g) and ammonium formate (322 g) were added. The reaction mixture was heated at reflux for 3 hours and cooled to 40 ° C. The catalyst was filtered off and the filtrate was concentrated to oil. Methylene chloride (5 L) and water (5 L) were added to the oil and the mixture was vigorously stirred. The layers were separated and the aqueous phase extracted with methylene chloride (1 L). The combined organic phases were washed with water (2 × 3 L), concentrated under reduced pressure, isopropanol was added and again concentrated under reduced pressure. Isopropanol (3 L) was added and the slurry granulated at 0 ° C. for 1 hour. The product was collected by filtration, washed with isopropanol and dried overnight at 50 ° C. under reduced pressure to give the title compound (547 g). HPLC analysis using the conditions set forth in Example 1 showed the product to be the title compound in 97% purity.
    Preparation Example 9
    (2R, 3S / 2S, 3R) -2- (2,4-difluorophenyl) -3- (pyrimidin-4-yl) -1- (1H-1,2,4-triazole-1- I) butan-2-ol
    (2R, 3S / 2S, 3R)-:( 2R, 3R / 2S, 3S) -3- (4-chloropyrimidin-6-yl) -2- (2,4-difluoro in methanol (700 mL) Rophenyl) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol (product of Example 10) (70 g), ammonium formate (24.1 g) and 10% (w / w) a mixture of palladium on carbon (water content 60% w / w) (John Johnson Metty type 87 L) (4.7 g) was heated to reflux under nitrogen atmosphere for 2 hours. After cooling to 25 ° C., the reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved in dichloromethane (500 mL) and washed with water (2 × 500 mL). The organic phase was dried over magnesium sulfate and concentrated under reduced pressure, and the resulting rubbery crystallized from isopropanol (250 mL) at -10 ° C. The product was collected by filtration and dried at 50 ° C. under reduced pressure to afford the title compound (38.1 g).
    1 H-NMR (300 MHz, CDCl 3 ): δ = 1.1 (d, 3H), 3.65 (q, 1H), 4.15 (d, 1H), 4.8 (d, 1H), 6.55 (s, 1H), 6.8 ( m, 2H), 7.4 (d, 1H), 7.5 (m, 1H), 7.6 (s, 1H), 7.9 (s, 1H), 8.75 (d, 1H), 9.15 (s, 1H) ppm.
    权利要求:
    Claims (39)
    [1" claim-type="Currently amended] In the presence of zinc, iodine and / or Lewis acid and an aprotic organic solvent, a compound of formula II is reacted with a compound of formula III (then optionally a compound of formula I A process for the preparation of a compound of formula (I) or an acid addition salt or base salt thereof:
    Formula I

    Formula II

    Formula III

    Where
    R is phenyl optionally substituted with 1 to 3 substituents each independently selected from halo and trifluoromethyl;
    R 1 is C 1 -C 6 alkyl;
    "Het" is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, oxo, benzyl and benzyloxy;
    X is chloro, bromo or iodo.
    [2" claim-type="Currently amended] The method of claim 1,
    How lead is also present.
    [3" claim-type="Currently amended] The method according to claim 1 or 2,
    How iodine is used.
    [4" claim-type="Currently amended] The method of claim 3, wherein
    A process carried out by mixing a compound of formula (II), a compound of formula (III) and iodine in an aprotic organic solvent with a mixture of zinc, iodine, optionally lead, optionally Lewis acid and aprotic organic solvent.
    [5" claim-type="Currently amended] The method according to any one of claims 1 to 4,
    If Lewis acid is used, the Lewis acid is zinc chloride, zinc bromide or zinc iodide.
    [6" claim-type="Currently amended] The method according to any one of claims 1 to 5,
    The aprotic organic solvent is tetrahydrofuran.
    [7" claim-type="Currently amended] The method according to any one of claims 1 to 6,
    A process in which acid addition salts of compounds of formula (I) are prepared.
    [8" claim-type="Currently amended] The method of claim 7, wherein
    Acid addition salts include hydrochloride, hydrogen bromide, hydrogen iodide, sulfate, nitrate, methanesulfonic acid salt, camphorsulfonic acid salt, R-(-)-10-camphorsulfonic acid salt, (+)- 3-bromo-10-camphorsulfonic acid salt, (-)-3-bromo-8-camphorsulfonic acid salt, phosphate salt, para-toluenesulfonic acid salt or benzenesulfonic acid salt, preferably hydrochloric acid How salt is.
    [9" claim-type="Currently amended] The method according to any one of claims 1 to 8,
    R is phenyl substituted with one or two substituents each independently selected from fluoro and chloro.
    [10" claim-type="Currently amended] The method of claim 9,
    R is phenyl substituted with one or two fluoro substituents.
    [11" claim-type="Currently amended] The method of claim 10,
    R is 2,4-difluorophenyl.
    [12" claim-type="Currently amended] The method according to any one of claims 1 to 11,
    R 1 is methyl.
    [13" claim-type="Currently amended] The method according to any one of claims 1 to 12,
    “Het” is pyrimidinyl optionally substituted with one to three substituents each independently selected from halo, oxo and benzyl.
    [14" claim-type="Currently amended] The method of claim 13,
    “Het” is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from fluoro, chloro, oxo and benzyl.
    [15" claim-type="Currently amended] The method of claim 14,
    “Het” is pyrimidinyl optionally substituted with 1 to 3 substituents each independently selected from fluoro and chloro.
    [16" claim-type="Currently amended] The method of claim 14,
    "Het" is pyrimidin-4-yl, 4-chloro-5-fluoropyrimidin-6-yl, 5-fluoropyrimidin-4-yl, 2-chloro-5-fluoropyrimidine-6- One, 2,4-dichloro-5-fluoropyrimidin-6-yl, 4-chloropyrimidin-6-yl or 1-benzyl-5-fluoropyrimidin-6-one-4-yl.
    [17" claim-type="Currently amended] The method of claim 16,
    “Het” is 4-chloro-5-fluoropyrimidin-6-yl.
    [18" claim-type="Currently amended] The method according to any one of claims 1 to 17,
    X is bromo.
    [19" claim-type="Currently amended] A process for preparing a compound of formula (IV) or an acid addition salt thereof, comprising the following steps (a) to (d):
    (a) reacting a compound of formula II with a compound of formula IIIA to provide a compound of formula IA in the presence of zinc, iodine and / or Lewis acid and an aprotic organic solvent;
    (b) optionally converting a compound of formula (IA) to an acid addition salt thereof;
    (c) reducing the compound of formula (IA) or an acid addition salt thereof to provide a compound of formula (IV); And
    (d) optionally converting the compound of formula IV to its acid addition salt:
    Formula IV

    Formula II

    Formula IIIA

    Formula IA

    Where
    R and R 1 are as defined above for the compound of formula I of claim 1,
    R 2 is H or fluoro,
    X is chloro, bromo or iodo,
    R 3 and R 4 are each independently selected from chloro and bromo, or one of R 3 and R 4 is chloro or bromo, and the other is H.
    [20" claim-type="Currently amended] The method of claim 19,
    The method in which lead is also present in step (a).
    [21" claim-type="Currently amended] The method of claim 19 or 20,
    How iodine is used in step (a).
    [22" claim-type="Currently amended] The method according to any one of claims 19 to 21,
    The aprotic organic solvent of step (a) is tetrahydrofuran.
    [23" claim-type="Currently amended] The method according to any one of claims 19 to 22,
    The acid addition salt of step (b) is a hydrochloride salt, methanesulfonic acid salt or p-toluenesulfonic acid salt.
    [24" claim-type="Currently amended] The method according to any one of claims 19 to 23,
    The reduction in step (c) is carried out by hydrogenation with a catalyst or by transition hydrogenation.
    [25" claim-type="Currently amended] The method of claim 24,
    A method in which reduction is carried out by transition hydrogenation.
    [26" claim-type="Currently amended] The method of claim 25,
    A process wherein the transition hydrogenation is carried out using palladium and ammonium formate.
    [27" claim-type="Currently amended] 27. The method of any of claims 19 to 26,
    The acid addition salt of step (d) is S-(+)-or R-(-)-10-camphorsulfonic acid salt.
    [28" claim-type="Currently amended] The method according to any one of claims 19 to 27,
    R is 2,4-difluorophenyl.
    [29" claim-type="Currently amended] The method according to any one of claims 19 to 28,
    R 1 is methyl.
    [30" claim-type="Currently amended] The method according to any one of claims 19 to 29,
    R 2 is fluoro.
    [31" claim-type="Currently amended] The method according to any one of claims 19 to 30,
    (i) R 3 is chloro and R 4 is H;
    (ii) R 3 is H and R 4 is chloro;
    (iii) R 3 and R 4 are both chloro.
    [32" claim-type="Currently amended] The method of claim 31, wherein
    R 3 is chloro and R 4 is H.
    [33" claim-type="Currently amended] 33. The method of any of claims 19-32,
    X is bromo.
    [34" claim-type="Currently amended] The method according to any one of claims 19 to 27,
    R is 2,4-difluorophenyl, R 1 is methyl, R 2 is fluoro, R 3 is chloro, R 4 is H and X is bromo.
    [35" claim-type="Currently amended] The method according to any one of claims 19 to 27,
    Compound of formula (IA) is 3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazole -1 day) butan-2-ol, 3- (2-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2 , 4-triazol-1yl) butan-2-ol, 3- (2,4-dichloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1 -(1H-1,2,4-triazol-1yl) butan-2-ol or an acid addition salt of any of these.
    [36" claim-type="Currently amended] The method according to any one of claims 19 to 27,
    Compound of formula IV is 2- (2,4-difluorophenyl) -3- (5-fluoropyrimidin-4-yl) -1- (1H-1,2,4-triazol-1-yl ) Butan-2-ol or an acid addition salt thereof.
    [37" claim-type="Currently amended] (i) (2R, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2, 4-triazol-1-yl) butan-2-ol;
    (ii) (2R, 3S / 2S, 3R)-or (2R, 3S) -3- (4-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl Acid addition salts, preferably hydrochloric acid salts of) -1- (1H-1,2,4-triazol-1-yl) butan-2-ol;
    (iii) 3- (2,4-dichloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazole -1-yl) butan-2-ol or acid addition salts thereof in (2R, 3S / 2S, 3R)-or (2R, 3S) -form or any of these;
    (iv) 3- (2-chloro-5-fluoropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazole-1 Acid addition salts of -yl) butan-2-ol or its (2R, 3S / 2S, 3R)-or (2R, 3S) -form or any of these;
    (v) 3- (1-benzyl-5-fluoropyrimidin-6-one-4-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4- Acid addition salts of triazol-1-yl) butan-2-ol or its (2R, 3S / 2S, 3R)-or (2R, 3S) -form or any of these; or
    (vi) 3- (4-chloropyrimidin-6-yl) -2- (2,4-difluorophenyl) -1- (1H-1,2,4-triazol-1-yl) butane- Acid addition salts of 2-ols or (2R, 3S / 2S, 3R)-or (2R, 3S) -forms or any of these
    A compound of formula (I) as defined in claim 1.
    [38" claim-type="Currently amended] (i) 6- (1-bromoethyl) -2,4-dichloro-5-fluoropyrimidine;
    (ii) 4- (1-bromoethyl) -6-chloropyrimidine;
    (iii) 6- (1-bromoethyl) -4-chloro-5-fluoropyrimidine;
    (iv) 1-benzyl-4- (1-bromoethyl) -5-fluoropyrimidin-6-one;
    (v) 6- (1-bromoethyl) -2-chloro-5-fluoropyrimidine; or
    (vi) 4- (1-bromoethyl) -5-fluoropyrimidine
    A compound of formula III as defined in claim 1.
    [39" claim-type="Currently amended] Ammonium salt of 2-chloro-6-ethyl-5-fluoro-4-hydroxypyrimidine.
    类似技术:
    公开号 | 公开日 | 专利标题
    FI107606B|2001-09-14|The process provides pharmaceutically valuable 1-, 3-, 5-substituted pyrrolidin-2-ones
    JP4725977B2|2011-07-13|Process for producing 2-dihaloacyl-3-amino-acrylic acid ester and 3-dihalomethyl-pyrazole-4-carboxylic acid ester
    US6579874B2|2003-06-17|Substituted azoles
    DE60132776T2|2009-02-12|Pyrimidine derivatives and their use for the manufacture of a triazolo pyrimidine carba nucleoside
    CA2285891C|2004-01-06|Triazole antifungal agents
    US5661151A|1997-08-26|Tetrahydrofuran antifungals
    JP5232230B2|2013-07-10|Method for producing voriconazole
    KR20160134672A|2016-11-23|2-|-1,1-difluoro-1-|-3-|propan-2-ols and processes for their preparation
    US5656629A|1997-08-12|6-substituted pyrazolo |pyrimidin-4-ones and compositions and methods of use thereof
    US4792561A|1988-12-20|Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
    KR850000887B1|1985-06-26|Process for preparing trisubstituted imidazole derivatives
    US4921862A|1990-05-01|Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
    FI93957C|1995-06-26|Process for the preparation of pyrimidines
    EP1263739B1|2008-01-02|Crystalline salts of 7-¬4-|-6-isopropyl-2-¬methyl|amino pyrimidin-5-yl -|-3,5-dihydroxyhept-6-enoic acid
    AU602638B2|1990-10-18|Triazole antifungal agents
    EP0145294B1|1989-10-18|Substituted triazoles, processes for making them, their use as fungicides and fungicidal compositions containing them
    CN1076019C|2001-12-12|Preparation of triazoles by organometallic addition to ketones and intermediates therefor
    KR101109215B1|2012-01-30|New intermediates of Voriconazole and preparation of Voriconazole using the same
    ES2592273T3|2016-11-29|Dihydropyridopyrimidines and dihydropyridazines substituted with 5-aryl and their use as mineralocorticoid antagonists
    US20110263666A1|2011-10-27| process for the preparation or purification of olmesartan medoxomil
    CZ282922B6|1997-11-12|Synthesis process of |-1,1-dimethylethyl-6-cyanomethyl -2,2-dimethyl-1,3-dioxan-4-acetate and intermediates used in such process
    TW201215601A|2012-04-16|Method for producing 1-triazole-2-butanol derivative
    US5405861A|1995-04-11|Triazole compounds and antifungal compositions thereof
    SK74397A3|1998-06-03|Process for preparing 5-£2-ethoxy-5-|-phenyl|-1-methyl-3-n-propyl-1,6-dihydro-7h- pyrazolo£4,3-d|-pyrimidin-7-one and intermediate products of this process
    JP2657324B2|1997-09-24|Phenylcarboxylic acid derivatives having a hetero ring
    同族专利:
    公开号 | 公开日
    RU2156760C2|2000-09-27|
    AU703337B2|1999-03-25|
    HK1014944A1|2002-08-23|
    US6946555B2|2005-09-20|
    NO980441L|1998-03-26|
    PL187227B1|2004-06-30|
    NO314938B1|2003-06-16|
    JP3211965B2|2001-09-25|
    WO1997006160A1|1997-02-20|
    HU9802766A2|1999-02-01|
    GB9516121D0|1995-10-04|
    CN1076019C|2001-12-12|
    AR003472A1|1998-08-05|
    IL122462A|2001-10-31|
    ZA9606587B|1998-02-02|
    CZ32798A3|1999-03-17|
    US6586594B1|2003-07-01|
    PE16897A1|1997-05-21|
    PT871625E|2004-04-30|
    IN190817B|2003-08-23|
    AU6740396A|1997-03-05|
    EG21200A|2001-01-31|
    EP0871625A1|1998-10-21|
    JP2001026583A|2001-01-30|
    DK871625T3|
    DK0871625T3|2004-03-29|
    IL122462D0|1998-06-15|
    JPH10510549A|1998-10-13|
    AT256679T|2004-01-15|
    CZ296975B6|2006-08-16|
    JP2001354670A|2001-12-25|
    BR9609960A|1999-02-02|
    TR199800170T1|1998-06-22|
    NO980441D0|1998-02-02|
    TW442480B|2001-06-23|
    CN1195346A|1998-10-07|
    DE69631160D1|2004-01-29|
    KR100269048B1|2000-10-16|
    JP3224532B2|2001-10-29|
    HU224339B1|2005-08-29|
    EP0871625B1|2003-12-17|
    IL131521A|2001-08-08|
    CA2228655C|2003-09-09|
    IL131521D0|2001-01-28|
    NZ315651A|1999-03-29|
    ES2210382T3|2004-07-01|
    DE69631160T2|2004-07-08|
    PL324922A1|1998-06-22|
    MY123062A|2006-05-31|
    HU9802766A3|2000-03-28|
    MX9801025A|1998-04-30|
    CA2228655A1|1997-02-20|
    US20030181720A1|2003-09-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    1995-08-05|Priority to GBGB9516121.2A
    1995-08-05|Priority to GB9516121.2
    1996-07-26|Application filed by 디. 제이. 우드, 무어 제임스 더블유, 화이자 리써치 앤드 디벨로프먼트 캄파니 엔.브이. 에스.에이
    1999-05-25|Publication of KR19990036174A
    2000-10-16|Application granted
    2000-10-16|Publication of KR100269048B1
    2009-06-11|First worldwide family litigation filed
    优先权:
    申请号 | 申请日 | 专利标题
    GBGB9516121.2A|GB9516121D0|1995-08-05|1995-08-05|Organometallic addition to ketones|
    GB9516121.2|1995-08-05|
    [返回顶部]